RxDoctor Payments Data

Nicholas Hanna, MD

Cardiovascular Disease · Tulsa, OKNPI 1225284094

Payments from drug & device makers

What this record shows

9 manufacturers reported payments, led by Edwards Lifesciences at 31.8% of the total. Reporting peaked in 2019 at $2,128 and has fallen 72.2% since, to $591 in 2025.

$7,908in general payments, 2019–2025

Across 61 payments — averaging $129.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Asahi Intecc USA, Inc.$2K
  • Abiomed$1K
  • Abbott$1K
  • Boston Scientific$587
  • Penumbra, Inc.$140
  • plus $328 from 3 others
$438,590in research payments, 2019–2025

Across 219 payments — averaging $2002.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cardiovascular Systems Inc.$188K
  • Janssen Research & Development, LLC$100K
  • Boston Scientific$57K
  • Amgen$52K
  • Abbott$42K

What the payments were for

  • Travel & lodging$4,62158%
  • Food & beverage$3,28742%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences19$2,517
Asahi Intecc USA, Inc.10$1,725
Abiomed5$1,326
Abbott13$1,285
Boston Scientific7$587
Penumbra, Inc.1$140
Inquis Medical, Inc.1$115
Medtronic4$108
Opsens Inc.1$104

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,908 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$248,686
Medicare patients
1,224
Services billed
3,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$221,604
XareltoRivaroxaban67$77,906
EntrestoSacubitril/Valsartan74$72,702
Repatha SureclickEvolocumab43$38,444
JardianceEmpagliflozin24$21,438
FarxigaDapagliflozin Propanediol25$13,806
Praluent PenAlirocumab11$11,997
BrilintaTicagrelor25$11,218
Atorvastatin Calcium299$7,380
Rosuvastatin Calcium116$3,255
Ranolazine ErRanolazine32$2,892
Metoprolol Succinate178$2,795
Isosorbide Mononitrate ErIsosorbide Mononitrate189$2,755
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$2,364
ClopidogrelClopidogrel Bisulfate155$2,281

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →